UFC 334 is scheduled for November 14, 2026, at Madison Square Garden in New York City and will feature an extensive fight card with 14 bouts, including two high-profile title fights. The main event will have heavyweight champion Ciryl Gane defending his title against the sixth-ranked Josh Hokit. Gane obtained undisputed champion status earlier in September after Tom Aspinall vacated the belt, ending a period during which the UFC heavyweight title had seen little decisive activity since October 2025.
The co-main event will spotlight Amanda Nunes, a former two-division UFC champion, coming out of retirement to challenge current bantamweight titleholder Kayla Harrison. Their bout had originally been planned for January 2026 but was postponed due to Harrison’s neck surgery. Harrison, an Olympic gold medalist in judo and former PFL lightweight champion, has made an impressive UFC debut and currently holds the women's bantamweight title, which she secured in June 2025.
Ciryl Gane, 36, has a solid championship track record despite past losses in title fights to notable fighters like Francis Ngannou and Jon Jones. After reclaiming the interim heavyweight belt in June by knocking out Alex Pereira, Gane now faces a rising contender, Josh Hokit, who secured his UFC contract in August 2025 and has since accumulated a strong record with several TKO wins. Hokit is now ranked sixth in the UFC heavyweight division, though he has drawn controversy for provocative remarks outside the octagon.
Amanda Nunes boasts an elite MMA career, debuting in UFC in 2013 and earning titles in both bantamweight and featherweight divisions during a dominant run until her initial retirement. Her return to face Kayla Harrison not only renews a fierce competitive rivalry but also marks a significant moment in women’s MMA. With Nunes’ storied history of victories over top fighters such as Ronda Rousey and Cris Cyborg, her fight against Harrison carries high stakes and intense anticipation from the MMA community.
Start the discussion with a take, question, or market read.